title: Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results.
abstract: The clinical safety and effectiveness of a subgingivally delivered biodegradable drug delivery system containing either 10% doxycycline hyclate (DH), 5% sanguinarium chloride (SC) or no agent (VC) was evaluated in a 9-month multi-center trial. The study was a randomized parallel design with 180 patients who demonstrated moderate to severe periodontitis. All patients had at least two quadrants with a minimum of four qualifying pockets > or = 5 mm that bled on probing. Two of the qualifying pockets were required to be > or = 7 mm. At baseline and at 4 months all qualified sites were treated with the test article administered via syringe. Probing depth reduction (PDR), attachment level gain (ALG), bleeding on probing reduction (BOP), and plaque index were determined monthly. Analysis of efficacy data from the 173 efficacy-evaluable patients indicated that all treatments gave significant positive clinical changes from baseline at all subsequent timepoints. DH was superior to SC and VC in PDR at all timepoints (P < or = 0.01 to 0.001) with a maximum reduction of 2.0 mm at 5 months. For ALG, DH was superior to VC at months 2, 3, 4, 5, 6, 8, and 9 (P < or = 0.04 to 0.002) and superior to SC at months 5, 6, 7, 8, and 9 (P < or = 0.01 to 0.001) with a maximum ALG of 1.2 mm at 6 months. For BOP reduction, DH was superior to VC at all time points (P < or = 0.05) and to SC at months 3, 5, 6, 8, and 9 (P < or = 0.03). For DH, the maximum ALG in deep (> or = 7 mm) pockets was 1.7 mm and PDR 2.9 mm compared to 0.8 mm and 1.6 mm, respectively for moderate (5 to 6 mm) pockets. Test articles were applied without anesthesia and no serious adverse events occurred in the trial. The results of this study indicate that 10% doxycycline hyclate delivered in a biodegradable delivery system is an effective means of reducing the clinical signs of adult periodontitis and exhibits a benign safety profile.
authors.affiliation: University of Pennsylvania, School of Dental Medicine, Philadelphia, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Polson
authors.forename: S
authors.initials: S
authors.lastname: Garrett
authors.forename: N H
authors.initials: NH
authors.lastname: Stoller
authors.forename: C L
authors.initials: CL
authors.lastname: Bandt
authors.forename: P J
authors.initials: PJ
authors.lastname: Hanes
authors.forename: W J
authors.initials: WJ
authors.lastname: Killoy
authors.forename: G L
authors.initials: GL
authors.lastname: Southard
authors.forename: S P
authors.initials: SP
authors.lastname: Duke
authors.forename: G C
authors.initials: GC
authors.lastname: Bogle
authors.forename: C H
authors.initials: CH
authors.lastname: Drisko
authors.forename: L R
authors.initials: LR
authors.lastname: Friesen
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000008:administration & dosage* / Q000627:therapeutic use; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage* / Q000627:therapeutic use; D053119:Benzophenanthridines; D001673:Biodegradation, Environmental; D003774:Dental Plaque Index; D004318:Doxycycline / Q000008:administration & dosage* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007546:Isoquinolines; D008297:Male; D008875:Middle Aged; D010512:Periodontal Index; D010513:Periodontal Ligament / Q000502:physiology; D010518:Periodontitis / Q000188:drug therapy*; D012044:Regression Analysis; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D000470:Alkaloids; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D053119:Benzophenanthridines; D007546:Isoquinolines; C005705:sanguinarine; D004318:Doxycycline